Treatment for Health Anxiety (Hypochondriasis)
Cognitive-behavioral therapy (CBT) should be the first-line treatment for health anxiety, with SSRIs (particularly fluoxetine) as an effective alternative or adjunctive option when CBT alone is insufficient.
Treatment Algorithm
First-Line: Cognitive-Behavioral Therapy
CBT demonstrates robust efficacy with large effect sizes (g = 0.79-0.95) and should be initiated as primary treatment 1, 2. The treatment achieves:
- Response rates of 66-76%
- Remission rates of 48-68%
- Sustained benefits at 3-year follow-up 3
CBT Components:
- Exposure therapy (confronting health-related fears and reducing safety behaviors)
- Cognitive restructuring (challenging catastrophic health beliefs)
- Duration: 12-20 sessions
- Both individual exposure therapy and cognitive therapy show equivalent efficacy 4
Second-Line: Pharmacotherapy with SSRIs
When CBT is unavailable, declined by patient, or provides insufficient response after 8 weeks, initiate fluoxetine as the SSRI with the strongest evidence 5.
Key pharmacotherapy findings:
- Fluoxetine demonstrated significant superiority over placebo in reducing hypochondriacal symptoms on the Whiteley Index 5
- Fluoxetine showed faster rate of improvement and better quality of life outcomes compared to placebo 5
- All SSRIs show beneficial effects in systematic reviews 6
Combined Treatment Approach
Joint treatment (CBT + fluoxetine) provides modest incremental benefit over monotherapy, with responder rates of 47.2% versus 41.8% for single treatments 5. Consider combination therapy for:
- Moderate to severe health anxiety
- Inadequate response to monotherapy after 8 weeks
- Significant comorbid depression or anxiety
Important Clinical Considerations
Avoid benzodiazepines: These carry increased risk of dependence, cognitive impairment, and should only be used short-term if absolutely necessary 7.
Monitor treatment response:
- Reassess monthly until symptoms subside 7
- If poor response after 8 weeks despite good compliance, modify treatment (add pharmacotherapy to CBT, switch medications, or intensify psychotherapy) 7
- Use standardized measures (Whiteley Index, H-YBOCS-M) to track progress 5
Address treatment barriers: Patients with health anxiety often avoid following through on referrals due to their anxious temperament—proactively assess compliance and satisfaction with treatment 7.
Evidence Strength and Nuances
The evidence strongly favors CBT, with exposure therapy showing particular promise for reducing safety behaviors (excessive doctor visits, body checking) 4. Notably, cognitive changes occur even with pure exposure therapy, suggesting that direct cognitive interventions may not be necessary for all patients 4.
While the single highest-quality RCT found fluoxetine superior to placebo but CBT not significantly different from placebo at week 24 5, this contradicts the broader meta-analytic evidence showing robust CBT effects 1, 2. The meta-analyses represent higher-level evidence with larger sample sizes and should guide treatment decisions.
Critical gap: Approximately 50% of patients do not achieve remission with current treatments 5, indicating need for treatment intensification or alternative approaches in non-responders.
Cost-Effectiveness
CBT for health anxiety is probably cost-effective given the substantial economic burden of untreated hypochondriasis (ranging from $857 to $21,138 per capita annually) 8 and the sustained long-term benefits of treatment 1, 3.